Clinical Report: Systemic Immune-Inflammation Index in Rheumatic Diseases

Overview

This systematic review and meta-analysis evaluated the systemic immune-inflammation index (SII) in patients with rheumatic diseases (RDs) compared to healthy controls. The findings indicate that SII values are significantly higher in RD patients.

Background

Rheumatic diseases (RDs) are a diverse group of immune-mediated conditions that can lead to significant morbidity if not diagnosed and treated promptly. Current diagnostic methods often lack specificity and may not accurately reflect disease activity. The SII, derived from standard blood count parameters, may provide a more accessible and interpretable biomarker for assessing inflammation in RDs.

Data Highlights

Key Findings

• Patients with RDs had significantly higher SII values compared to healthy controls.
• The standardized mean difference (SMD) for SII was 0.83 with a 95% confidence interval of 0.69 to 0.97.
• No significant associations were found between SII and various demographic or clinical factors in meta-regression analysis.
• Subgroup analysis showed significant SII differences across most RD categories, except for fibromyalgia and connective tissue disease.
• Lower heterogeneity was observed in European studies compared to those conducted in Asia and Africa.

Clinical Implications

Further research is needed to establish clinically relevant thresholds for SII.

Conclusion

The SII may serve as a valuable adjunctive biomarker in the assessment of rheumatic diseases, warranting further investigation to enhance its clinical application.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Author(s)/Org, Source, Year -- Title
10. Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis | Scientific Reports
11. Systemic immune-inflammation index and systemic inflammation response index in systemic lupus erythematosus: a meta-analysis - PubMed
12. Frontiers | Systemic immune-inflammation index as a versatile biomarker in autoimmune disorders: insights from rheumatoid arthritis, lupus, and spondyloarthritis
13. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
14. https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltdf97323a3723de0f/lupus-guideline-sle-2025.pdf
15. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update - ScienceDirect
16. 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs | Rheumatology | Oxford Academic
17. Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs